Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
about
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist
P2860
Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@ast
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@en
type
label
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@ast
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@en
prefLabel
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@ast
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@en
P2093
P2860
P356
P1433
P1476
Puquitinib, a novel orally ava ...... against acute myeloid leukemia
@en
P2093
Chengying Xie
Mingyue Zhen
Yongping Xu
Yulan Wang
P2860
P304
P356
10.1111/CAS.13263
P50
P577
2017-04-18T00:00:00Z